Key result
Pharmacological inhibition of CXCR4 with AMD3465 significantly reduced diabetes-induced perivascular cardiac fibrosis from 13.1% to 7.6% in a mouse model of type 1 diabetes.
Why the study?
Does CXCR4 antagonism reduce cardiac fibrosis in animal models of type 1 and type 2 diabetes?
Does CXCR4 antagonism reduce cardiac fibrosis in animal models of type 1 and type 2 diabetes?
Absolute Event Rate: 7.6% vs 13.1%
p-value: p=<0.01
Pharmacological inhibition of CXCR4 significantly reduces diabetes-induced cardiac fibrosis in both type 1 and type 2 diabetic animal models, independent of blood pressure lowering.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for CXCR4 antagonism in diabetic cardiomyopathy; leaves open translation to human type 1 or type 2 disease.
Chu et al. (2015) studied Diabetic cardiac fibrosis. CXCR4 antagonist (AMD3465 or AMD3100) vs. Vehicle control was evaluated on Perivascular collagen volume fraction (p=<0.01). Pharmacological inhibition of CXCR4 with AMD3465 significantly reduced diabetes-induced perivascular cardiac fibrosis from 13.1% to 7.6% in a mouse model of type 1 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: